Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No volume but holding on a very down day
looks like shorts will have opportunities galore over the next week.
Opti
I wish we would hear of Co Diagnostic plans to expand production or partner with others. We need more testing, so the demand is there to support expansion.
Opti
And look who shows up! LOL
Opti
This approval, preceding earnings by two weeks is a great ramp up.
Looking very positive.
Opti
Moderna’s 370% Rally Has Cost Short Sellers $1.5 Billion in 2020
By Bailey Lipschultz
July 17, 2020, 3:51 PM EDT
Those betting against high-flying vaccine developer Moderna Inc. have taken their lumps this year with the biotech’s 370% rally costing short sellers almost $1.5 billion, according to financial analytics firm S3 Partners.
The Cambridge, Massachusetts-based biotech has boomed into a $36 billion behemoth amid excitement for its vaccine to treat the novel coronavirus. Still, even with the stock’s parabolic move this week, it’s primed for a squeeze with short investor losses potentially outweighing overbought price conviction, S3 Partners managing director Ihor Dusaniwsky said in a note.
Moderna surged 6.9% to a record on Wednesday after early results from its Covid-19 vaccine candidate drew Wall Street praise. With the company set to start a final-stage study of the vaccine this month, excitement for the company and nerves for short sellers could push the stock even higher.
https://www.bloomberg.com/news/articles/2020-07-17/moderna-s-370-rally-has-cost-short-sellers-1-5-billion-in-2020?srnd=premium
Opti
The reason we are stalled is because people are selling and moving on to better performing stocks. Other stocks like INO are killing us.
Opti
Another frustrating Monday. I fear the shorts and manipulators have beaten this one into the ground. I have seen this before where a great company is simply beaten soo soundly that it fails to ever recover. If they were shorting to gain cheap shares before a sharp rise, they may have defeated their own purpose.
This stock has to join the other COVID plays and advance quickly to the high 20's.
Opti
Update from H.C. Wainwright
U.S. COVID-19 spikes and testing backlog suggest growing testing demand ahead. The first wave of infections in the U.S. is still trending around the highest levels seen to date. Last Friday, the U.S. broke prior single-day COVID-19 record by registering over 66,000 new cases, according to a Johns Hopkins University tracker. California, Texas, and Florida saw record daily coronavirus spikes during the last week and are now the country’s largest COVID-19 hotspots. Specifically, the Florida Department of Health reported 15,299 new cases yesterday, the highest number of new cases reported in a single day by any state since the COVID-19 pandemic began. The U.S. now has roughly 3.3M accumulative cases and over 135K COVID-19 patients have died. It is not clear at this juncture when the first wave might end or—as economic activities resume and schools reopen in the coming months—whether there could be a second wave or if the first wave simply extends into the coming fall-winter season. What is clear now is that testing demand has been steadily increasing and is likely to continue to remain at a substantial level in the coming quarters, in our view. In fact, as reported in the Wall Street Journal yesterday, the COVID-19 testing system is reaching the brink in the U.S. as growing demand surpasses what the nation’s labs can handle, resulting in supply shortages and backlogs. Outside the U.S., Brazil, India, and South Africa are registering the greatest rises in COVID-19 cases, according to the United Nations (UN) health agency. Therefore, we believe Co-Diagnostics should continue to ship a high volume of its Logix Smart™ COVID-19 test kits, with an increasing volume shipped to U.S. customers. In addition, the India market is serviced by the company’s joint venture, CoSara, with manufacturing facilities located in India. As a reminder, the company had approximately $100M worth of tests in mid-May that are slated to be shipped. In the wake of the accelerating COVID-19 spread, we reiterate our Buy rating and $35 price target.
Logix Smart COVID-19 test’s high accuracy independently validated by multiple institutions. The company’s COVID-19 test has been independently validated by PathWest Laboratories in Australia, the Indian National Institute of Pathology, and the Mexican Department of Epidemiology. This qualitative real-time reverse transcription PCR (RT-PCR) test has a limit of detection at 4.29 copies/µL, 99.52% sensitivity and 100.00% specificity. Time to detection is 63-90 minutes. PCR (molecular) testing is the gold standard to detect active COVID-19 infections, based on FDA guidelines. Of note, CoSara’s Sarageneâ„¢ COVID-19 test, which uses the same reagents as in Logix Smart COVID-19, has been approved for sale in India.
Valuation and risks. Our 12-month price target is based on an enterprise value-to-sales (EV/Sales) multiple of 9x and projected sales of $3.93 per share for the next 12 months ($108M sales from 2Q20 to 1Q21, and 27.5M shares outstanding). Sales of CoSara have yet to be integrated into the company’s top-line revenue. Risks include, but are not limited to: (1) lower-than-projected product uptake; (2) inability to maintain regulatory compliance; (3) inability to develop additional products targeting segments beyond infectious disease in developing markets; and (4) potential dilution risk.
Full Report can be found at: http://codiagnostics.com/wp-content/uploads/2020/07/HCW-13JUL20-Update.pdf
Opti
Mask stocks rally after New Jersey takes action
Jul. 8, 2020 1:20 PM ET|About: Alpha Pro Tech, Ltd. (APT)|By: Clark Schultz, SA News Editor
New Jersey Governor Phil Murphy says masks are now required in the state outdoors when social distancing isn't possible.
The development has sent mask manufacturers Alpha Pro Tech (APT +8.2%), Allied Healthcare Products (AHPI +7.8%) and Lakeland Industries (LAKE +6.0%) higher.
Gaps (GPS +0.4%) is slightly up on the day, but Etsy (ETSY -1.0%) is lower.
Goldman Sachs thinks the mask mandate is positive for the market in general. The firm sees upside as more Americans wear masks and more local governments institute rules, pointing to data showing the high correlation in Europe and Asia of widespread mask usage through policy or cultural norms to fewer COVID-19 cases, hospitalizations and fatalities. GS estimates national face covering in the U.S. could prevent a 5% hit to national GDP.
Opti
I despise these no volume down days. You wait all weekend for a pop and instead get a fizzle.
Opti
Co-Diagnostics: COVID-19 Test Sales Push Up Its Price
Jul. 6, 2020 1:22 AM ET|1 comment | About: Co-Diagnostics, Inc. (CODX),
Wang Financial Research
Arbitrage, small-cap, mid-cap
Summary
Co-Diagnostics develops tools for detecting infectious diseases, cancer, and agricultural software.
It reported stock gains of more than 2,190%.
In a recent press release, the company talked about additional 20 million tests, which would make revenue of $600 million a realistic number.
The shares are currently sold for $18-20. With 2020 forward sales of $600 million, I would say that shares would trade at a minimum of $36-40.
Adding the target market of hepatitis B, hepatitis C, HIV, malaria, Zika and other illnesses, the company is targeting a total amount of annual tests of approximately 1.993 billion.
https://seekingalpha.com/article/4357019-co-diagnostics-covidminus-19-test-sales-push-up-price?utm_medium=email&utm_source=seeking_alpha&mail_subject=codx-co-diagnostics-covid-19-test-sales-push-up-its-price&utm_campaign=rta-stock-article&utm_content=link-2
Opti
June was a pretty steady month
Friday closes
7/3 18.89
6/26 18.08
6/19 17.24
6/12 15.57
6/5 15.98
Opti
you can't control this. you are just along for the ride. this was not unexpected or novel. it has happed before and will do so again. follow the money and never fall in love with the company. be smart.
Opti
This drop is due to the downgrades, not just a "sell on the news" event. INO may be loosing ground in the vaccine race.
Sad.
Opti
Inovio under pressure as Pfizer vaccine data highlights its lack thereof
Jul. 1, 2020 11:01 AM ET|About: Inovio Pharmaceuticals... (INO)|By: Douglas W. House, SA News Editor
Inovio Pharmaceuticals (INO -15.4%) is down, albeit on average volume, pressured by a string of downgrades after it released "positive results" on COVID-19 vaccine candidate INO-4800 that was woefully light on data, a shortcoming that significantly contrasts with the data-heavy announcement from Pfizer and BioNTech on their candidate BNT162b1.
Opti
COVID yoyo's CODX and INO. AH CODX now ahead of INO, after INO took a substantial lead last week. I used to try flipping these two and APT, but settled on CODX about a month ago. Helps me sleep at night instead of wondering if I made the wrong move.
Planning to hold until mid-August and then take my profits and live on them for the next 20 years.
Opti
Inovio down nearly another 10% as two downgrades hit
Jul. 1, 2020 8:24 AM ET|About: Inovio Pharmaceuticals, ... (INO)|By: Stephen Alpher, SA News Editor
Inovio (NASDAQ:INO) dropped 15% yesterday following positive results from its Phase 1 trial for Covid-19 DNA vaccine candidate INO-4800. The dip perhaps was to have been expected, with investors selling the news following the fast run higher in the stock leading up to the trial results.
"This preliminary data is likely to raise more questions," says Stifel's Stephen Willey, who is waiting for the full results to appear in a peer-reviewed journal before joining the bulls on the stock.
Roth's Jonathan Aschoff, meanwhile, is "not encouraged" by the "very limited" data, and the absence of immune response details. "We are unimpressed that further preclinical work is required, rather than proceeding straight to later stage trials." He downgrades to Sell from Neutral, continuing with an $11 price target, suggesting more than 50% downside.
The bulls at Maxim - noting a 700% run higher in the stock this year - downgrade to Hold from Buy.
Opti
Finally back over $19.
Now if we can just keep the momentum.
Opti
We news to produce volume.
Opti
We have not talked for some time about the possibility of a major grant or contract. This is behind the INO surge from 12 to 33 just this week. I hope we experience the same.
Opti
Unreal!
INO has doubled in just 3 days!
Opti
Inovio Pharmaceuticals: Smart Devices And A Smart Investment
Jun. 25, 2020 2:09 PM ET | About: Inovio Pharmaceuticals, Inc. (INO)
David M. Eberhart
David M. Eberhart
Long only, Growth, dividend investing
(231 followers)
Summary
Another multi-million dollar award from the U.S. Department of Defense validates Inovio's 21st century DNA technology.
The DoD stake in Inovio's Smart devices signals a "smart" buy for investors.
Inovio Pipeline Update: HPV.
On Tuesday, June 23, 2020, Inovio Pharmaceuticals (INO) announced that it had received a $71 million contract from the U.S. Department of Defense (DoD) to scale up manufacturing of its CELLECTRA 3PSP smart devices, as well as the procurement of CELLECTRA 2000 for Inovio's COVID-19 DNA vaccine, INO-4800. This new award continues to strengthen and ensure the ongoing relationship between the United States Department of Defense and Inovio Pharmaceuticals, a relationship that dates back over the last several years.
Inovio CEO Dr. Joseph Kim added this regarding their upcoming work with the DoD,
We look forward to working closely with DoD, JPEO-CBRND and JPL-CBRND-EB to provide much needed protection to DoD personnel and their families through development of a safe and effective vaccine against COVID-19. This next generation smart device leverages the efficacy delivery and safety track record of an earlier version that has received CE mark certification and has been used in clinical trials to safely dose more than 2,000 patients in over 7,000 administrations of INOVIO's DNA medicines. The current DoD contract further supports INOVIO's large-scale production of devices and arrays to deliver potentially hundreds of millions of doses of INO-4800 next year to combat the global COVID-19 pandemic."
In my last article, "Inovio Pharmaceuticals: Positioning for a Global Opportunity", I wrote about the critical importance of this smart device for the effective delivery of Inovio's DNA vaccines. In essence, I reported that without this device, INO vaccines are essentially worthless and ineffective. Therefore, with the DoD granting an award to scale up manufacturing as well as procurement for these devices, it serves to validate and acknowledge the significance of the marriage between electroporation (EP) for the delivery of Inovio's DNA vaccines.
As a result of the DoD award, INO churned over 172M shares in volume for the day (a bit more than 110% of the entire float of outstanding shares), gained an additional 40% in SP appreciation and raised the market cap to $3.41B.
Source: Tradingview.com
A Smart Decision
So, what makes this investment by the DoD such a smart decision? I'll break this down into small parts so as to not lose the reader in the science of electroporation (EP) in order to illustrate the marriage between (EP) and the introduction of (DNA) into living cells and why the DoD gets it.
1. It all starts with identifying a sequence of the genetic code found in the disease target. Once the identification of a genetic sequence has been selected, the DNA plasmid (usually a circular ring of a harmless fragment of E Coli DNA), is encoded with only that portion of the sequence deemed safest to deliver an optimal response, hence the expression 'optimized DNA plasmid'.
2. After pre-clinical trials on small animals (mice and guinea pigs), challenge studies of infected larger animals such as rabbits, ferrets and primates are initiated and the results analyzed to confirm safety and efficacy, as well as some time to allow for peer reviews, before a vaccine can move into human trials. This can take years however, Inovio has the advantage of years of prior research that make their rapid response platform to infectious diseases attractive to the DoD.
3. Next follows the introduction of measured doses of the pre-clinically tested DNA plasmid into humans. These occur in PHI, PHII and PHIII trials. The introduction of the DNA medicine is done via a common ordinary syringe into the upper layers of the skin.
4. Once injected into the skin via syringe it is followed by electroporation or better stated, a series of pulsed electrical discharges which open up small holes in nearby cells which allow the plasmids to enter cells. The pulses are spaced milliseconds apart and are administered using the 3PSP device, an electric toothbrush sized device (pictured below). The device is an un-tethered, AA" battery operated and uses disposable cartridge tips. It can be used for both intra-dermal (ID) and intra-muscular (IM) delivery.
It's safe because the plasmid is only encoded with a nano piece of the gene sequence, in the case of COVID-19, a part of the spike protein. Once inside the cell, after EP, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune response. In lay terms, the body recognizes an unfamiliar visitor and activates the immune system to provide front line protection before the disease can infiltrate and infect a potential host.
For those new to the science, pictured below is an illustration of a circular DNA plasmid (in blue) and the added snippet of an antigen (in green) which depicts the DNA technology that Inovio identifies as "SynCon" or synthetic consensus.
Source: Inovio.com
Armed with all of this knowledge it makes sense for the DoD to capitalize on their partnership with Inovio. Inovio has repeatedly shown a proven safety profile while dosing over 2,000 patients with EP electrical stimulation. Additionally, it has shown to be the most efficient method to effectively permit DNA to pass through the protective membrane walls of living plants, animals and humans, a process known as 'transfection'. Furthermore, the appropriate genetic sequence selection for plasmids used for delivering coded instructions that activates the immune system is part of the Inovio IP portfolio and why INO can design a vaccine in a matter of hours.
As described and detailed above, Inovio has produced an attractive platform for partnership with the DoD in order to protect its military members and their families with a safe and effective vaccine. This also has significant meaning in more than one way as two of my children are military members (US Army & USN) and the third is married to another (USAF). There isn't a vaccine I would desire more for their protection, while serving this great country, than to see the approval of INO-4800. Inovio remains laser focused because saving lives and protecting our country is in their DNA, too.
this has already ended badly for shorties. I feel soooooooooooo sorry for them.
Opti
I will take an 8-fold increase any day. Weird kind of bamboozling.
Opti
Imagine: "this will end badly" for people who are up 8-fold. Really, are they going to be spoiled by riches? Is that how this end's badly? Maybe they will crash their new Lamborghini? I guess that would be bad.
Opti
Citron Hit Piece; I was wondering when they would strike.
Citron tweets on animal spirits driving Inovio Pharmaceuticals
Jun. 25, 2020 11:17 AM ET|About: Inovio Pharmaceuticals... (INO)|By: Douglas W. House, SA News Editor
In a tweet, noted short seller Citron Research reiterates its bearish view on Inovio Pharmaceuticals (INO +14.4%), a favorite among Robinhood traders.
In April, it published a report questioning the veracity of its assertion that its "secret algorithm" enabled it to design a COVID-19 vaccine candidate in three hours, comparing the company to one-time early-stage star Theranos, since imploded after its false technology claims were exposed.
Citron sees the stock returning to $14 (~49% downside risk) in "short order."
Shares are up over eight-fold this year. The company sports a $4.4B market cap despite no product sales and no track record of advancing candidates into the marketplace.
Here is their tweet:
Citron Research
@CitronResearch
·
1h
$INO has become a chew toy for RobinHood traders. Expect $INO back to $14 in short order This is the chart of $INO vs the 5 companies chosen by $CDC to lead vaccine. Even most spec $MRNA trades @ 27x vs. INO @ 158x. Trading can be profitable but vaccines are not.
Opti
Your statement is false since they stand today as a late file. Fact.
Opti
beware of lagging financial reports. Not trying to be negative on ABMC, but I held a stock that eventually was suspended because they did not file the financial reports.
Opti
INO, APT, and other COVID stocks continue to soar. Will CODX follow suit? I hope so, as I have consciously not switched to these other stocks that I have held in the past 3 months. I am hoping CODX catches INO in share price in the coming week.
Opti
Not into wild predictions. One day at a time.
Opti
that is a February 2019 article. it has NOTHING to do with today's situation. What kind of BS are you trying to spread here?
Opti
this is all about future earnings. none of the current ratios are relevant.
Opti
40 % increase in one day.
Opti
Amazing Day!
INO up 44%
APT up 12.2 %
CODX up 13.8%
Opti
Amazing Day!
APT up 12.2 %
INO up 44%
CODX up 13.8%
Opti
Amazing Day!
CODX up 13.8%
APT up 12.2 %
INO up 44%
Opti
Congratulations to all longs.
Well deserved day of reward.
Opti